Ng George K 4

What Happened

• Processa Pharmaceuticals CEO George K. Ng reported an open‑market purchase (code P) of 1,843 shares on May 15, 2026 at $2.97 per share, totaling $5,474. This filing amends prior reporting errors noted in a footnote.

Key Details

• Transaction date: May 15, 2026
• Trade type: Open-market purchase (code P)
• Shares acquired: 1,843 shares at $2.97 each; total value $5,474
• Footnote: Shares were adjusted to correct immaterial errors from a Form 4 filed May 1, 2026 — the corrected price for an April 30, 2026 purchase is $2.71 (not $2.69), reducing that April 30 purchase by 15 shares
• Shares owned after transaction: Not specified in the provided filing excerpt
• Filing date: May 19, 2026 (the Form 4 covers the May 15 transaction); the filing does not indicate a late‑filing flag in the provided information

Context

• This was a straightforward open‑market purchase (not an option exercise or gift). Purchases by insiders can be of interest to investors as one piece of information about management's view, but the trade size here ($5.5k) is relatively small and should be weighed with other data and company developments.